Ociperlimab Enrolling by Invitation Phase 3 Trials for Advanced Malignant Neoplasm Treatment

Indications	Status	Purpose	Phase
DBCOND0033490 (Advanced Malignant Neoplasm)	Enrolling by Invitation	Treatment	3

clinicaltrials.gov Identifier	Title	Drugs
NCT04164199	Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies	Fruquintinib (DB11679) Lenvatinib (DB09078) Ociperlimab (DB18947) Pamiparib (DB14769) Sitravatinib (DB15036) Surzebiclimab (DB16669) Temozolomide (DB00853) Tislelizumab (DB14922) Zanidatamab (DB15471)